JPMorgan Chase & Co. Sells 14,599 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

JPMorgan Chase & Co. lessened its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 25.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 43,105 shares of the company’s stock after selling 14,599 shares during the quarter. JPMorgan Chase & Co.’s holdings in Takeda Pharmaceutical were worth $613,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new position in Takeda Pharmaceutical during the 3rd quarter worth $40,000. BNP Paribas Financial Markets grew its holdings in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after buying an additional 2,596 shares during the last quarter. Smithfield Trust Co increased its position in Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after acquiring an additional 1,490 shares during the period. Erste Asset Management GmbH acquired a new stake in Takeda Pharmaceutical in the 3rd quarter worth $52,000. Finally, Hexagon Capital Partners LLC increased its stake in Takeda Pharmaceutical by 34.3% during the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after acquiring an additional 1,129 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK stock opened at $13.35 on Tuesday. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $13.31 and a two-hundred day moving average of $13.89. The company has a market capitalization of $42.46 billion, a P/E ratio of 23.01, a P/E/G ratio of 0.24 and a beta of 0.51.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.